Gapping up
In reaction to strong earnings/guidance:
- PEP +3%
M&A news:
- MIME +0.6% (acquires Ataata)
- SHPG +0.5% (Shire plc acquisition by Takeda (TKPYY) receives unconditional clearance from the FTC)
Other news:
- OCX +60.7% (reports 'encouraging' new study results for lung cancer blood test)
- XLRN +7.6% (Celgene and Acceleron announce Luspatercept achieved primary and all key secondary endpoints in Phase III BELIEVE study)
- MNOV +7.5% (reports new clinical data from subgroup analyses of completed clinical trial of MN-166)
- CBPO +4.7% (Ping An Insurance said to be weighing a rival bid for CBPO, according to Bloomberg)
- KMDA +3.8% (receives positive scientific advice from the EMA's CHMP related to the development plan for its proposed pivotal Phase 3 study for Inhaled Alpha-1 Antitrypsin therapy)
- TSLA +2.6% (reports that the company could be planning a China plant that would have a 500k car/year capacity)
- SFUN +2.4% (Fang signs non-binding memorandum to acquire 10% equity interest in Chongquing Wanli New Energy for RMB200 mln)
- CELG +2.1% (Celgene and Acceleron announce Luspatercept achieved primary and all key secondary endpoints in Phase III BELIEVE study)
- NOK +0.9% (Nokia and China Mobile (CHL) sign one-year frame agreement - valued at up to EUR 1 bln - to support the Chinese mobile operator's transition to a future-oriented network infrastructure), .
Analyst comments:
- KBH +4.4% (upgraded to Positive from Neutral at Susquehanna)
- CASA +4.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SFIX +3.8% (initiated with Overweight at KeyBanc Capital Mkts)
- HEAR +2% (initiated with a Buy at DA Davidson)
- CHKP +2% (upgraded to Buy from Neutral at BTIG Research)
- WYNN +1.5% (upgraded to Buy from Hold at Stifel)
- FCAU +0.7% (upgraded to Buy from Neutral at UBS)
- WTW +0.6% (initiated with Overweight at KeyBanc Capital Mkts; tgt $115)
![]()